ALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI Pharmaceuticals We are investigating the fairness of the proposed sale of Alimera Sciences to ANI Pharmaceuticals for $5.50 per share in cash, plus a CVR.

Alimera Sciences Proposes Public Offering of Common Stock ATLANTA, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a pharmaceutical company that specializes in research, development and commercialization of...

Alimera Sciences announces clinical presentations and sponsored Symposia at ASRS 2016 Annual meeting ATLANTA, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today...

Alimera Sciences to Report Fourth Quarter 2015 Financial Results on March 2, 2016 ALPHARETTA, Ga., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences (NASDAQ:ALIM), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today...